The Group's principal activity is to develop technologies and products to treat cancers and infectious diseases. It primarily develops Oncophage (R). Lead development programs include immunotherapeutics that are based on a specific class of proteins known as heat shock proteins (HSPs) and an immune system adjuvant called QS-21. The products under development include Oncophage (R), Aroplatin, ATRA-IV, AG-702, QS-21 Adjuvant, CD91 and CD1. The related business activities include product research and development activities, regulatory and clinical affairs, establishing manufacturing capabilities, production for clinical trials and administrative and corporate development activities.
Alacra Alerts:
Receive alerts on the latest reports on Antigenics, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
